KR101990096B1 - 알파-시누클레인 항체와 그것의 용도 - Google Patents

알파-시누클레인 항체와 그것의 용도 Download PDF

Info

Publication number
KR101990096B1
KR101990096B1 KR1020157025875A KR20157025875A KR101990096B1 KR 101990096 B1 KR101990096 B1 KR 101990096B1 KR 1020157025875 A KR1020157025875 A KR 1020157025875A KR 20157025875 A KR20157025875 A KR 20157025875A KR 101990096 B1 KR101990096 B1 KR 101990096B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
fragment
syn
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157025875A
Other languages
English (en)
Korean (ko)
Other versions
KR20160010402A (ko
Inventor
엘 아그나프 오마르
Original Assignee
유나이티드 아랍에미리트 대학교
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/781,158 external-priority patent/US20140241987A1/en
Application filed by 유나이티드 아랍에미리트 대학교 filed Critical 유나이티드 아랍에미리트 대학교
Publication of KR20160010402A publication Critical patent/KR20160010402A/ko
Application granted granted Critical
Publication of KR101990096B1 publication Critical patent/KR101990096B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
KR1020157025875A 2013-02-28 2014-02-27 알파-시누클레인 항체와 그것의 용도 Active KR101990096B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/781,158 US20140241987A1 (en) 2013-02-28 2013-02-28 Alpha-synuclein antibodies and uses thereof
US13/781,158 2013-02-28
US14/138,347 2013-12-23
US14/138,347 US9534044B2 (en) 2013-02-28 2013-12-23 Alpha-synuclein antibodies and uses thereof
PCT/IB2014/059287 WO2014132210A1 (en) 2013-02-28 2014-02-27 Alpha-synuclein antibodies and uses thereof

Publications (2)

Publication Number Publication Date
KR20160010402A KR20160010402A (ko) 2016-01-27
KR101990096B1 true KR101990096B1 (ko) 2019-06-19

Family

ID=51388371

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157025875A Active KR101990096B1 (ko) 2013-02-28 2014-02-27 알파-시누클레인 항체와 그것의 용도

Country Status (6)

Country Link
US (2) US9534044B2 (enExample)
EP (1) EP2961774B1 (enExample)
JP (1) JP6261621B2 (enExample)
KR (1) KR101990096B1 (enExample)
CN (1) CN105121473B (enExample)
WO (1) WO2014132210A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102448128B1 (ko) * 2014-09-11 2022-09-27 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 미스폴딩된 단백질의 검출
CN107074938A (zh) * 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
WO2016075516A1 (en) * 2014-11-14 2016-05-19 United Arab Emirates University Compounds for use as imaging agents
US11136401B2 (en) 2015-03-27 2021-10-05 University Of Southern California Car t-cell therapy directed to LHR for the treatment of solid tumors
AU2016270474A1 (en) 2015-06-04 2018-01-04 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP4000632A1 (en) 2016-06-02 2022-05-25 MedImmune Limited Antibodies to alpha-synuclein and uses thereof
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
US10889635B2 (en) * 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
EA039807B1 (ru) * 2017-01-06 2022-03-16 ЭйБиЭл БИО ИНК. Антитело к -синуклеину и его применение
EP3583124A1 (en) * 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3618870A4 (en) 2017-05-01 2021-04-21 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES
WO2019018607A1 (en) * 2017-07-20 2019-01-24 Enzo Biochem, Inc. IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF
EP3672635A4 (en) * 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
CA3082559A1 (en) * 2017-11-17 2019-05-23 Abl Bio Inc. Antibodies to .alpha.-synuclein and uses thereof
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
EP3725806A4 (en) * 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
JP7719713B2 (ja) * 2018-10-07 2025-08-06 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア α－シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法
JP2022520106A (ja) 2019-02-15 2022-03-28 ユニバーシティ オブ サザン カリフォルニア Ｌｙｍ－１およびｌｙｍ－２抗体組成物ならびに改善されたｃａｒ構築物
US11208477B2 (en) * 2019-04-01 2021-12-28 Novo Nordisk A/S Antibodies and use thereof
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
KR102444797B1 (ko) * 2019-06-14 2022-09-20 에이비엘바이오 주식회사 α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
BR112022000778A2 (pt) * 2019-07-16 2022-04-12 Univ Washington Anticorpos anti-grp78 e método de uso dos mesmos
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
NL2025332B1 (en) 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
MA60122B1 (fr) * 2020-06-26 2025-07-31 Bioarctic Ab Anticorps se liant à la protofibrille d'alpha-synucléine
US20230365665A1 (en) 2020-09-17 2023-11-16 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
WO2022060236A1 (en) * 2020-09-17 2022-03-24 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
CN113912713B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白的单克隆抗体及其应用
CN113912715B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白抗体及其相关产品和应用
CN114853887B (zh) * 2022-03-08 2022-12-20 骏蓦(北京)生物科技有限公司 一种特异性结合α-突触核蛋白的抗体及其应用
CN115032400A (zh) * 2022-03-28 2022-09-09 首都医科大学附属北京天坛医院 α-突触核蛋白在辅助诊断神经退行性疾病中的用途
CN116286668A (zh) * 2023-02-13 2023-06-23 贵安新区康顺生物科技有限公司 一种杂交瘤细胞株及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177972A1 (en) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106271A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
US5948658A (en) * 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
JP4860477B2 (ja) * 2003-11-20 2012-01-25 メディミューン，エルエルシー ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
KR101456728B1 (ko) * 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
GB0716885D0 (en) 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
CN101570575B (zh) * 2008-04-30 2012-02-29 北京市肿瘤防治研究所 Sncg的单克隆抗体及其应用
CA2746778C (en) * 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
DE102011008153B4 (de) 2011-01-08 2018-08-09 Aj Roboscreen Gmbh Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177972A1 (en) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules

Also Published As

Publication number Publication date
US10208111B2 (en) 2019-02-19
EP2961774A4 (en) 2016-10-26
KR20160010402A (ko) 2016-01-27
EP2961774B1 (en) 2021-12-29
HK1217107A1 (zh) 2016-12-23
US20140241984A1 (en) 2014-08-28
JP2016511254A (ja) 2016-04-14
WO2014132210A1 (en) 2014-09-04
US20170190765A1 (en) 2017-07-06
EP2961774A1 (en) 2016-01-06
CN105121473B (zh) 2019-11-12
JP6261621B2 (ja) 2018-01-17
CN105121473A (zh) 2015-12-02
US9534044B2 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
KR101990096B1 (ko) 알파-시누클레인 항체와 그것의 용도
KR102695287B1 (ko) 항-phf-타우 항체 및 이의 용도
AU2017219749B2 (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
US20250320286A1 (en) Antibodies to pyroglutamate amyloid-b and uses thereof
IL263530B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
NZ738595A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
KR20190057004A (ko) 알파-시누클레인에 대한 항체 및 그 용도
CN114206444A (zh) 用于治疗和诊断的新分子
US20140241987A1 (en) Alpha-synuclein antibodies and uses thereof
KR102523019B1 (ko) 항-a베타 항체 및 이의 용도
US20250101087A1 (en) Anti-amyloid beta antibodies and methods of using the same
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途
RU2830101C1 (ru) Антитело к angptl3 и его применение
HK1217107B (en) Alpha-synuclein antibodies and uses thereof
WO2022238459A1 (en) New humanized anti-vegfc antibodies and uses thereof
HK40071061A (en) Novel molecules for therapy and diagnosis
EA045911B1 (ru) АНТИТЕЛА К ПИРОГЛУТАМАТ-β-АМИЛОИДУ И ИХ ПРИМЕНЕНИЕ
OA18779A (en) Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150918

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180808

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20180808

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180912

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190130

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190501

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190611

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220510

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230511

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250415

Start annual number: 7

End annual number: 7